Highest-materiality recent filing
Galectin Q1 net loss narrows to $5.1M; belapectin data at EASL, FDA meeting ahead
Net loss of $5.1M ($0.08 per share) vs $9.6M ($0.15) in Q1 2025; R&D expense fell to $2.2M from $6.5M.
Galectin Therapeutics reports FY2025 net loss $31M; belapectin data for EASL upcoming
Net loss $31.0M ($0.48/share) vs $47.2M ($0.76) in 2024; R&D expense down to $14.3M from $36.6M.
Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line
FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.
Galectin reports NAVIGATE biomarker data consistent with clinical benefit; FDA package submitted
In patients with ELF >11.3 (high-risk), new varices occurred in 22.7% on belapectin vs 42.9% on placebo.
Galectin reports Q3 net loss of $0.13/sh; cash $11.5M; NAVIGATE data submitted to FDA
Net loss of $8.2M ($0.13/share) vs $11.2M ($0.18/share) in Q3 2024; R&D spend down to $2.6M as NAVIGATE trial ended.
Galectin Therapeutics presents NAVIGATE trial: belapectin reduces varices, biomarkers improve
Belapectin 2 mg/kg reduced new varices vs placebo across all ELF risk categories at 18 months; in highest risk (ELF>11.3): 22.7% vs 42.9%.
Galectin Q2 net loss $7.6M ($0.12/sh); secures $10M credit line from chairman
Net loss applicable to common stockholders of $7.6M ($0.12 per share) vs $12.4M ($0.20) in Q2 2024.
Richard E. Uihlein provides up to $10M unsecured line of credit; draws through April 2026, principal & interest due Sept 30, 2026.
NAVIGATE trial: belapectin 2mg significantly reduces new varices in MASH cirrhosis patients
In per-protocol, belapectin 2mg reduced new varices incidence at 18 months (p=0.04) vs placebo.
Galectin Therapeutics Q1 net loss $9.6M; Belapectin shows liver stiffness reduction at EASL
Net loss for Q1 2025 was $9.6M ($0.15 per share) vs $11.5M ($0.19) in Q1 2024.
Belapectin shows 49.3% reduction in new varices in MASH cirrhosis patients at EASL 2025
Belapectin 2 mg/kg reduced new varices by 49.3% vs placebo (p=0.04) in per-protocol population (n=287).
Galectin Therapeutics reports FY2024 net loss of $47.2M; NAVIGATE varices reduction in per-protocol
Net loss $47.2M ($0.76/sh) vs $44.5M ($0.74/sh) in 2023; R&D spend $36.6M up from $32.1M.
Galectin reports 68.1% reduction in new varices with belapectin in U.S. patients from NAVIGATE trial
Per-protocol U.S. patients (n=186): 68.1% reduction in new varices with belapectin 2 mg vs placebo (p=0.02).
In ITT (N=355), primary composite endpoint not statistically significant; varices incidence reduced 43.2% with 2mg/kg vs placebo.
Net loss $11.2M ($0.18/share) vs $14.0M ($0.24) in Q3 2023; R&D expense $7.6M, G&A $1.5M.
NAVIGATE Phase 2b/3 trial of belapectin on track for interim top-line analysis in December 2024.
Net loss $11.5M ($0.19 per share) for Q1 2024, unchanged from Q1 2023.
Galectin Therapeutics reports FY2023 net loss of $44.8M; cash runway through March 2025
Net loss applicable to common stockholders of $44.8M ($0.74/share) vs $38.9M ($0.65/share) in FY2022.
Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.
On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.
Max materiality 0.85 · Median 0.60 · Most common event other_material